stockrowZymeworks Inc.
ZYME Healthcare Biotechnology
Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024.
- Revenue
- −90.6%
- EPS
- −2,166.7%
- Free cash flow
- −385.5%
Quarter to June 2026, against a year earlier
Follow ZYME
Alert me
Zymeworks Inc. (ZYME) Return on invested capital
Zymeworks Inc.'s return on invested capital over the twelve months to 30 June 2026 was 0.00%, up 145.7 percentage points from fiscal 2025 (−145.7%). Over the past ten years it has ranged from −405.2% (fiscal 2015) to 11,268.0% (fiscal 2022); the current reading is higher than 18% of that period. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −145.7% | (69.85) |
| FY2024 | −75.8% | 19.52 |
| FY2023 | −95.4% | (11,363.32) |
| FY2022 | 11,268.0% | 11,267.96 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | 19.64 |
| FY2017 | −19.6% | 54.27 |
| FY2016 | −73.9% | 331.25 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | 43.0% |
| VCEL Vericel Corporation compare | 7.88% |
| VERA Vera Therapeutics, Inc. compare | 0.00% |
| ZYME Zymeworks Inc. | 0.00% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.00% |
| COAG Hemab Therapeutics Holdings, Inc. compare | 0.00% |
| SEPN Septerna, Inc. compare | −189.0% |
| IMNM Immunome, Inc. compare | −3,323.0% |
| BHVN Biohaven Ltd. compare | −6,659.9% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on ZYME
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement